⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BBOT News
BridgeBio Oncology Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
BBOT
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com
BBOT
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BBOT
Form 8-K
sec.gov
BBOT
Form 8-K
sec.gov
BBOT
BBIO
AMGN
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
globenewswire.com
BBOT
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
globenewswire.com
BBOT
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
globenewswire.com
BBOT
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
globenewswire.com
BBOT
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BBOT